Atezolizumab + Tiragolumab + Ipatasertib for Cancer
(UmbrellaMAX Trial)
Trial Summary
Do I have to stop taking my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the study team or your doctor.
What data supports the effectiveness of the drug combination Atezolizumab, Tiragolumab, and Ipatasertib for cancer?
The combination of tiragolumab and atezolizumab has shown effectiveness in treating solid cancers, including non-small cell lung cancer, in multiple trials. Additionally, atezolizumab has demonstrated promising results when combined with other treatments in various cancers, suggesting potential benefits when used with ipatasertib.12345
Is the combination of Atezolizumab, Tiragolumab, and Ipatasertib generally safe for humans?
Atezolizumab, a part of the treatment, can cause immune-related side effects like skin rash, liver issues, and thyroid problems, but these are usually manageable. Serious side effects like kidney injury and low platelet count are rare. There is no specific safety data available for the combination with Tiragolumab and Ipatasertib.16789
What makes the drug combination of atezolizumab, tiragolumab, and ipatasertib unique for cancer treatment?
This drug combination is unique because it combines immune checkpoint inhibitors (atezolizumab and tiragolumab) with ipatasertib, which targets cancer cell growth pathways, potentially enhancing the immune response against cancer cells and offering a novel approach compared to standard treatments.1251011
What is the purpose of this trial?
The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.
Research Team
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Eligibility Criteria
This trial is for cancer patients who were part of a previous Genentech or Roche study and are still benefiting from the treatment but can't get it outside the study. They must start this extension within 7 days after their last dose in the original study and be able to follow this new study's rules.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants continue to receive Roche investigational medicinal product (IMP) monotherapy or in combination with other agents as per parent protocol
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension
Participants may continue treatment with Roche IMP(s) if they do not have local access to the study treatment
Treatment Details
Interventions
- Ipatasertib
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University